Disclaimer

The alfapump® system is currently not approved in Canada for commercial use. DSR® therapy is still in development and is currently not approved in the United States or Canada. Any statements regarding safety and efficacy arise from ongoing pre-clinical and clinical investigations which have yet to be completed. Sequana Medical makes no claims of safety or effectiveness of the DSR® therapy in the U.S. or Canada. There is no link between the DSR® therapy and ongoing investigations with the alfapump® system in Europe, the United States or Canada.

Tag

Regulated
PRESS RELEASE REGULATED INFORMATION 22 May 2025, 06:00 pm CEST Ghent, Belgium, 22 May 2025 – Sequana Medical NV (Euronext Brussels: SEQUA) (the “Company” or “Sequana Medical“), a pioneer in the treatment of drug-resistant fluid overload in liver disease, heart failure and cancer, announces today that all proposed resolutions submitted to the Annual and Extraordinary...
Read More
PRESS RELEASE REGULATED INFORMATION 14 May 2025, 18:00 CEST Ghent, Belgium, 14 May 2025 – Sequana Medical NV (Euronext Brussels: SEQUA) (the “Company” or “Sequana Medical“), a pioneer in the treatment of drug-resistant fluid overload in liver disease, heart failure and cancer, announces today that in the context of contributions in kind of certain receivables...
Read More
PRESS RELEASE REGULATED INFORMATION 8 May 2025, 18:00 pm CEST Ghent, Belgium – 8 May 2025 – Sequana Medical NV (Euronext Brussels: SEQUA) (the “Company” or “Sequana Medical“), a pioneer in the treatment of drug-resistant fluid overload in liver disease, heart failure and cancer, announces today that it received a transparency notification in relation to...
Read More
PRESS RELEASE REGULATED INFORMATION INSIDE INFORMATION 7 May 2025,18:00 pm CEST Ghent, Belgium, 7 May 2025 – Sequana Medical NV (Euronext Brussels: SEQUA) (the “Company” or “Sequana Medical“), a pioneer in the treatment of drug-resistant fluid overload in liver disease, heart failure and cancer, announces today that it issued a second subscription request notice in...
Read More
PRESS RELEASE REGULATED INFORMATION 28 April 2025,18:00 pm CEST Ghent, Belgium, 28 April 2025 – Sequana Medical NV (Euronext Brussels: SEQUA) (the “Company” or “Sequana Medical“), a pioneer in the treatment of drug-resistant fluid overload in liver disease, heart failure and cancer, announces today that, as a result of a subscription to new shares by...
Read More
PRESS RELEASE REGULATED INFORMATION 25 April 2025, 18:00 pm CEST Ghent, Belgium – 25 April 2025 – Sequana Medical NV (Euronext Brussels: SEQUA) (the “Company” or “Sequana Medical“), a pioneer in the treatment of drug-resistant fluid overload in liver disease, heart failure and cancer, announces today that it received a transparency notification in relation to...
Read More
Publication of Annual Report 2024 PRESS RELEASE REGULATED INFORMATION 22 April 2025, 18:00 pm CEST Ghent, Belgium – 22 April 2025 – Sequana Medical NV (Euronext Brussels: SEQUA) (the “Company” or “Sequana Medical“), a pioneer in the treatment of drug-resistant fluid overload in liver disease, heart failure and cancer, today invites the holders of securities...
Read More
PRESS RELEASE REGULATED INFORMATION 8 April 2025, 18:00 CEST Ghent, Belgium, 8 April 2025 – Sequana Medical NV (Euronext Brussels: SEQUA) (the “Company” or “Sequana Medical“), a pioneer in the treatment of fluid overload in liver disease, heart failure and cancer, announces today that, in the context of a contribution in kind of a EUR...
Read More
PRESS RELEASE REGULATED INFORMATION – INSIDE INFORMATION 18 March 2025, 07:00 CET alfapump® – US FDA approval of alfapump® for the treatment of recurrent or refractory ascites due to liver cirrhosis; US commercial launch planned for mid Q3 2025 DSR® – Publication of RED DESERT and SAHARA data in peer-reviewed “European Journal of Heart Failure”...
Read More
PRESS RELEASE REGULATED INFORMATION 10 February 205, 17:30 CET Ghent, Belgium – 10 February 2025 – Sequana Medical NV (Euronext Brussels: SEQUA) (the “Company” or “Sequana Medical“), a pioneer in the treatment of fluid overload in liver disease, heart failure and cancer, announces today that it received a transparency notification in relation to the entities...
Read More
1 2 3 10

PRESS RELEASES

SUBSCRIBE TO OUR PRESS RELEASES